Business
INmune Bio Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most
About this update from Inmune Bio Inc.
[{"type":"text","content":" An in-depth analysis of MRI gray matter microstructure following treatment with XPro™ shows that the greatest improvement was in the earliest and most affected regions of the AD brain; an effect that was accompanied by an improvement in neuronal proteins and EEG changes associated with core AD pathologies. Boca Raton, Florida, Oct. 17, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, highlights some important findings from data presented at the 16th annual Clinical Trial in Alzheimer’s Disease (CTAD) to be held October 24-27 in Boston, MA. INmune is enrolling AD patients into a global, blinded, randomized Phase II trial. “The Phase Ib trial was designed to demonstrate that XPro™ reverses neuroinflammation and has been confirmed by previously presented data,” said CJ Barnum Ph.D., VP of CNS Drug Development at INmune Bio. “The trial further demonstrated many incremental downstream benefits of reversing neuroinflammation with XPro™. We continue to harvest information from the extensive data collected from the trial to improve our understanding of the role of neuroinflammation in AD, the mechanism-of-action (MOA) of XPro™, and provide insight into future clinical trial design.” Summary of CTAD Presentations featuring XPro: P186: Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer’s Disease. In a small group of mild to moderate AD patients, the feasibility of home, self-administered electroencephalogram (EEG) using the novel system from Cumulus Neuroscience was tested. The study confirmed the feasibility of collecting quality EEG signals at home with strong patient participation and evidence of functional benefit as demonstrated by an acute and chronic boost in P300 amplitude changes after treatment with XPro™. P081: Changes in neurology related CSF proteome after treatment with XPro1595 for Alzheimer’s disease. Treatment with XPro™ was associated with dose-dependent improvement in neurology-related proteins that are the most strongly associated with the core AD pathologies of amyloid-beta (Aβ) and phosphorylated tau (pTau), in this sample. These findings provide further evidence that XPro™ is targeting the neu...